Ultimovacs ASA (ULTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ultimovacs ASA (ULTI) has a cash flow conversion efficiency ratio of -0.299x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-24.70 Million ≈ $-2.60 Million USD) by net assets (Nkr82.67 Million ≈ $8.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ultimovacs ASA to measure how much of total assets are equity-financed.
Ultimovacs ASA - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ULTI operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Ultimovacs ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultimovacs ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Advani Hotels & Resorts (India) Limited
NSE:ADVANIHOTR
|
0.016x |
|
Daiyang Metal
KO:009190
|
-0.016x |
|
Electra Battery Materials Corp
V:ELBM
|
-0.046x |
|
AGX Group Berhad
KLSE:0299
|
0.075x |
|
SRG HOUSING FINANCE ORD (BSE)
NSE:SRGHFL
|
-0.337x |
|
Edip Gayrimenkul Yatirim Sanayi ve Ticaret AS
IS:EDIP
|
0.008x |
|
MEDIANA Co.Ltd
KQ:041920
|
-0.016x |
|
Mida Leasing Public Company Limited
BK:ML
|
0.018x |
Annual Cash Flow Conversion Efficiency for Ultimovacs ASA (2016–2024)
The table below shows the annual cash flow conversion efficiency of Ultimovacs ASA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Ultimovacs ASA (ULTI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr82.67 Million ≈ $8.70 Million |
Nkr-163.40 Million ≈ $-17.19 Million |
-1.977x | -190.92% |
| 2023-12-31 | Nkr279.39 Million ≈ $29.40 Million |
Nkr-189.83 Million ≈ $-19.98 Million |
-0.679x | -82.06% |
| 2022-12-31 | Nkr449.35 Million ≈ $47.28 Million |
Nkr-167.69 Million ≈ $-17.65 Million |
-0.373x | -75.92% |
| 2021-12-31 | Nkr593.15 Million ≈ $62.42 Million |
Nkr-125.83 Million ≈ $-13.24 Million |
-0.212x | +4.27% |
| 2020-12-31 | Nkr488.38 Million ≈ $51.39 Million |
Nkr-108.22 Million ≈ $-11.39 Million |
-0.222x | -56.42% |
| 2019-12-31 | Nkr444.63 Million ≈ $46.79 Million |
Nkr-62.99 Million ≈ $-6.63 Million |
-0.142x | +55.04% |
| 2018-12-31 | Nkr159.90 Million ≈ $16.83 Million |
Nkr-50.39 Million ≈ $-5.30 Million |
-0.315x | -92.70% |
| 2017-12-31 | Nkr166.48 Million ≈ $17.52 Million |
Nkr-27.23 Million ≈ $-2.86 Million |
-0.164x | +60.13% |
| 2016-12-31 | Nkr75.82 Million ≈ $7.98 Million |
Nkr-31.10 Million ≈ $-3.27 Million |
-0.410x | -- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.